As a complement to the hallmarks of cancer, I delineate six temporal landmarks in cancer’s life cycle—from the transformation of normal cells to clinical disease—and argue that the failure to control transitions between these stages underlies the limits of current therapeutic strategies. Cancer’s trajectory is marked by early activation of epigenetic and developmental programs (e.g., EMT, stemness, angiogenesis), the establishment of pre-metastatic niches via exosomes, and organism-wide metabolic reconfiguration that culminates in cachexia and systemic dysfunction. The tumor is not a passive growth, but an active instigator of systemic rewiring, leveraging inflammation, immunosuppression, and neuroendocrine stress pathways. Emerging tools such as RNA velocity, trajectory inference, and ecotyping offer promising avenues for mapping cancer progression and tailoring interventions. Rather than targeting isolated genetic events, a therapeutic shift is proposed: intervening at organismal nodes of vulnerability, decoding intercellular communication networks, and restoring systemic resilience. This holistic model reframes cancer prevention, interception, and treatment as an integrative effort to disrupt cancer’s systemic cooptation and reestablish organismic control.